Search
POT-4
go.drugbank.com/drugs/DB06056InvestigationalPOT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
Categories: Heterocyclic Compounds, 1-RingXTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. … It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
AZD-8330
go.drugbank.com/drugs/DB06061InvestigationalAZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.
Categories: Heterocyclic Compounds, 1-RingKAI-1455
go.drugbank.com/drugs/DB06064ExperimentalKAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.
XMT-1001
go.drugbank.com/drugs/DB06069InvestigationalXMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. … It is a water-soluble macromolecular conjugate of camptothecin (CPT).
Categories: Compounds used in a research, industrial, or household settingSNX-5422
go.drugbank.com/drugs/DB06070InvestigationalAs an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers. … SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingCitatuzumab Bogatox
go.drugbank.com/drugs/DB06072InvestigationalVB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.
Linifanib
go.drugbank.com/drugs/DB06080InvestigationalLinifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels … Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.
Synonyms: 1-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-3-(2-FLUORO-5-METHYLPHENYL)UREA, UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingTapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalIt is available as a topical cream to be applied to the affected area once daily. … Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis.
Synonyms: 3,5-Dihydroxy-4-isopropyl-trans-stilbeneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates